Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer
The addition of cadonilimab to standard chemotherapy for first line treatment of HER-2-negative advanced gastric cancer may not be considered a cost-effective option compared to chemotherapy alone. However, for the subgroup of patients with PD-L1CPS ≥ 5, the ICER was 26,813.44 USD per QALY, indicating that this treatment approach could potentially be deemed cost-effective in China.
Authors
- Zhiwei Zheng (ORCID: https://orcid.org/0000-0002-7815-3221)
- Qingsheng Yang (ORCID: https://orcid.org/0000-0002-6486-7346)
- Longfeng Zhang
Institutions
- Fujian Medical University (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Shantou Central Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-07-21
- DOI
- https://doi.org/10.3389/fpubh.2025.1644176
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00